COMPASS Pathways

Compass Pathways Plc functions as an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

COMPASS Pathways reports Q4 earnings, faces challenges, explores opportunities

COMPASS Pathways showcased progress in its clinical programs, financial performance, and strategic initiatives. Despite challenges in trial protocols and financial losses, the company remains focused on advancing its treatment options and exploring growth opportunities.

COMPASS Pathways advances Phase 3 TRD program amidst financial challenges

COMPASS Pathways is making progress in their Phase 3 TRD program and maintaining a strong financial position for future developments.
Acceptance of new CPT codes and engagement with health systems present growth opportunities for the company.
However, challenges like financial losses, mixed views on commercialization, and operational differences exist.
Overall, COMPASS Pathways is strategically positioned to capitalize on the evolving landscape of psychedelic therapies.

COMPASS Pathways progresses in trials amidst market challenges and opportunities

COMPASS Pathways is advancing well in trials for treatment-resistant depression and strengthening its market position through IP protection and regulatory milestones.
Challenges lie in differentiation from competitors and establishing unique value propositions, but opportunities exist in FDA support, market growth, and funding flexibility.
Overall, the company's performance, financial stability, and strategic moves position it favorably in the evolving landscape of psychedelic therapies.

COMPASS Pathways reports strong Q3 earnings, eyes transformative 2024

COMPASS Pathways demonstrated robust financial performance in Q3 2023, with strong cash reserves and a strategic private placement financing, positioning the company well for upcoming milestones.
While facing challenges in patient recruitment and trial complexities, COMPASS is leveraging AI models and expanding clinical sites to optimize operations and drive therapeutic innovation.
With Phase III data on the horizon and ongoing advancements in research and development, COMPASS Pathways is poised for a transformative year in 2024, capitalizing on growth opportunities and research insights.

COMPASS Pathways advances COMP360 trials amid financial challenges

COMPASS Pathways' financials show investment in research and development despite net losses, with a strong cash position.
Progress in key trials for COMP360 in TRD and positive safety data indicate promising developments in mental health treatment.
Challenges in enrollment, delays in data, and regulatory monitoring require strategic navigation for future success.
Opportunities lie in collaborations, potential indications, and a focused approach to TRD treatment with COMP360.

COMPASS Pathways advances in clinical trials and strategic partnerships

COMPASS Pathways showcased strong clinical and financial performance in Q1 2024 earnings call, emphasizing progress in Phase III trials and positive PTSD study results
While facing challenges in risk mitigation and therapy comparisons, the company's strategic collaborations and upcoming data releases offer promising opportunities for growth

Compass Pathways faces trial delays, strengthens leadership for commercial success

Compass Pathways navigates delays in pivotal trials while focusing on data disclosure and commercial readiness. New leadership strengthens strategic direction and commercial landscape. Challenges include trial complexities and managing attrition rates, with opportunities in leveraging Phase III data and commercial collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2022 and gave an update on recent progress across its business.

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Conference call to be held at 8:00am ET (1:00pm UK) Conference call to be held at 8:00am ET (1:00pm UK)

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023

Ginkgo Bioworks Holdings

Intellia Therapeutics

These stocks are risky. But they just might deliver huge gains if analysts are right.

3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street

FAT Brands

Innovative Industrial Properties

McDonald's

Philip Morris

Rogers Communications

Constellation Brands

Following a rough year, investors seeking positive returns might want to consider going a bit controversial with sin stocks. Understandably, with the political winds turning progressive, people nowadays turn a stink eye toward cynicism.

7 Tempting Sin Stocks to Buy for Promising Profits

Atai Life Sciences BV

Cybin

Ameri Holdings

GH Research PLC

Mind Medicine MindMed

Advisorshares Psychedelics ETF

Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.

The 7 Most Promising Psychedelic Stocks to Buy in February

Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?

Psychedelic Sunday: Competitive Strategies

COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.

Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?

Seelos Therapeutics

What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.

Scrutinizing Psychedelic Stocks

Amazon

Ford Motor Company

Fisker Inc

Medical Properties Trust

CarParts.com, Inc.

Toast

It is currently as good a time as ever for long-term investors to buy stocks. With that in mind, I decided to look for seven cheap stocks trading under $20  to buy and hold forever.

7 Stocks Under $20 to Buy and Hold Forever

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II bipolar disorder

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

Major positive shifts are happening, but the field faces new headwinds too.

3 Big Trends Shaking Up Psychedelic Stocks

LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Evercore ISI HealthCONx Conference at 9:15am ET on 30 November 2022.

COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference

COMPASS Pathways plc (NASDAQ:CMPS ) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Steven Schultz - SVP, IR George Goldsmith - Co-Founder and Executive Chairman Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Mike Falvey - CFO Conference Call Participants Charles Duncan - Cantor Fitzgerald Neena Bitritto-Garg - Citi Ritu Baral - Cowen Patrick Trucchio - H.C. Wainwright & Company François Brisebois - Oppenheimer Bert Hazlett - BTIG Esther Hong - Loop Capital Sumant Kulkarni - Canaccord Genuity Michael Okunewitch - Maxim Group Operator Good day, ladies and gentlemen, and welcome to the COMPASS conference Third Quarter Call.

COMPASS Pathways plc (CMPS) Q3 2022 Earnings Call Transcript

LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2022 and gave an update on recent progress across its business.

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

After a single 25mg dose of COMP360 psilocybin therapy, approximately 30% of patients with

COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine

LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2022, and provide an update on recent business developments on 3 November 2022.

COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022

COMPASS Pathways PLC Sponsored ADR (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

COMPASS Pathways PLC Sponsored ADR (CMPS) Upgraded to Buy: What Does It Mean for the Stock?

First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022

COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today the agenda for its virtual Capital Markets Day on 12 October 2022 at 8:00 am ET (1 pm UK).

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

Catalyst Pharmaceuticals

Their low price tags belie their massive long-term potential.

2 No-Brainer Stocks to Buy Right Now for Less Than $15

It's risky, and you'll need to wait a while for a payoff, assuming the stars align for there to be one.

Is Now a Good Time to Invest In Psychedelics Stocks?

LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at Jefferies Innovation in Mental Health Summit at 8:30am ET on 22 September 2022.

COMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit

They haven't experienced any setbacks, but their shares are still down.

Buying These 2 Battered Growth Stocks Right Now Could Be Brilliant

This week, we're talking about my Big Three investing themes for the rest of the year (and beyond). You've probably heard me talk about each at one point or another.

News for COMPASS Pathways Stock (CMPS)